Mynvax is a clinical-stage vaccine biotechnology company focused on developing innovative recombinant vaccines that are thermostable, specifically targeting respiratory viral infections. The company has made significant strides in vaccine design, notably creating a thermotolerant COVID-19 vaccine that is effective against various viral variants. This vaccine is particularly aimed at ensuring accessibility for low and lower-middle-income countries, reflecting Mynvax's commitment to global health equity. Founded in 2017, the company boasts a team of highly qualified scientists and has garnered support from prominent institutions, including the Indian Institute of Science and the Department of Biotechnology, Government of India.

The core technologies employed by Mynvax revolve around protein stabilization and design, which are critical for developing their novel vaccines. By leveraging their intellectual property and scientific expertise, Mynvax aims to enhance the efficacy and stability of vaccines against respiratory viruses. The company is actively pursuing commercial development partnerships with vaccine manufacturers to bring their innovative products to market, thereby contributing to the broader fight against respiratory viral diseases.

India

Mynvax is a developer of novel recombinant vaccines to fight the human influenza virus and COVID19. The company is focused on developing next-generation vaccines for influenza and other respiratory viruses. Mynvax has raised a total funding of $7.22M over 3 rounds from various investors. It is a clinical stage vaccine biotechnology company with a vision to create efficacious vaccines for respiratory viruses.

Infectious Diseases

Brigade MLR Centre, No 50, 3rd Floor, Vani Vilas Road, Basavanagudi, Bangalore KA 560004

Mynvax

Company Details